A retrospective study of vedolizumab in patients with ulcerative colitis (UC) and Crohn's disease (CD)
Latest Information Update: 07 Jan 2017
Price :
$35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 07 Jan 2017 New trial record